Phase II, proof-of-concept trial of VX 661 in combination with ivacaftor in patients with cystic fibrosis who have one copy of the F508del mutation and one copy of the G551D mutation

Trial Profile

Phase II, proof-of-concept trial of VX 661 in combination with ivacaftor in patients with cystic fibrosis who have one copy of the F508del mutation and one copy of the G551D mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2015

At a glance

  • Drugs Ivacaftor (Primary) ; Tezacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2015 Status changed from recruiting to completed, according to a Vertex Pharmaceuticals media release.
    • 21 Oct 2013 New trial record
    • 17 Oct 2013 Results from this trial are expected in the first quarter of 2014, according to a Vertex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top